drugset / Trial / NCT00003773
IM-862 in Treating Patients With Recurrent Ovarian Cancer
Phase 1
Completed
43 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of IM-862 in treating patients who have recurrent ovarian cancer after treatment with chemotherapy and surgery.
Timeline
- Start
- 1999-02
- Primary completion
- 2000-07
- Completion
- 2001-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | oglufanide | Small molecule | — | Intranasal |